The population density of Cambridge, MA was 18,114 in 2018. The population density of Albany, NY was 4,577 in 2018.
Population Density
Population Density is computed by dividing the total population by Land Area Per Square Mile.
Above charts are based on data from the U.S. Census American Community Survey | ODN Dataset | API -
Geographic and Population Datasets Involving Albany, NY or Cambridge, MA
- API
NYCHA Development Data Book
data.cityofnewyork.us | Last Updated 2024-05-13T15:53:04.000ZContains the main body of the "Development Data Book". The Development Data Book lists all of the Authority's Developments alphabetically and includes information on the development identification numbers, program and construction type, number of apartments and rental rooms, population, number of buildings and stories, street boundaries, and political districts.
- API
Short-term Industry Projections
data.ny.gov | Last Updated 2024-03-06T19:36:11.000ZShort-term Industry Projections for a 2 year time horizon are provided for the state and 10 labor market regions to provide individuals and organizations with an industry outlook.
- API
Long-term Industry Projections
data.ny.gov | Last Updated 2023-06-30T17:36:30.000ZLong-term Industry Projections for a 10 year time horizon are provided for the state and 10 labor market regions to provide individuals and organizations with an industry outlook.
- API
Waste Tire Abatement Sites
data.ny.gov | Last Updated 2022-08-12T17:59:04.000ZInformation on designated waste tire abatement sites in New York State, including approximate size, location, and abatement status.
- API
Daily Vehicle Miles of Travel: Beginning 1985
data.ny.gov | Last Updated 2022-02-15T22:29:27.000ZVMT is an estimate of travel based on traffic counts taken along the roads in New York State. Each year travel is estimated as part of the annual report to the Federal Highway Administration through the Highway Performance Monitoring System software application. The VMT estimate is stratified by the roadway Functional Classification of Principal Arterials, Minor Arterials, Collectors, and Local Roads & Street. The VMT data from 1985 through the current year is available.
- API
Real Property Assessment Equity Statistics By Municipality: Beginning 2004
data.ny.gov | Last Updated 2024-03-05T19:24:08.000ZThe Department of Taxation and Finance annually produces a report documenting the results of the Market Value Survey pertaining to property assessment. The report contains the staff findings regarding assessment equity by municipality in New York State, that is, the degree to which assessments are at a uniform percentage of their market value. Equity is measured primarily by two statistics — the coefficient of dispersion (COD) and the price-related differential (PRD). For more information please go to: http://www.tax.ny.gov/research/property/default.htm
- API
Rates of COVID-19 Cases or Deaths by Age Group and Updated (Bivalent) Booster Status
data.cdc.gov | Last Updated 2023-06-01T16:51:17.000ZData for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status Dataset and data visualization details: These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023. Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be
- API
Risk of Infected Blacklegged Tick Encounter: Adults (Oct to Dec): Beginning 2008
health.data.ny.gov | Last Updated 2024-05-01T18:57:20.000ZTick-borne diseases, such as Lyme disease, anaplasmosis and babesiosis, are a significant issue in New York (NY), impacting well over 10,000 individuals yearly. The New York State Department of Health (NYSDOH) has a responsibility to perform surveillance to monitor and track different kinds of tick-borne diseases. While most surveillance is done via reportable cases of human illness, tick-borne diseases can also be monitored by collecting ticks from the environment (called active surveillance) and testing them for bacteria, viruses, and parasites known to cause illness in people (collectively called pathogens). Active surveillance allows local county health departments in NY, excluding New York City (NYC), to have a better understanding of the tick populations present in the state, the species composition of the tick population, and the rate at which ticks are infected with different pathogens. The Department started testing ticks in 2002 in limited areas; testing statewide began in 2008. Further information on NYSDOH active tick surveillance can be found at the URL below and in the Data Methodology section below. https://www.health.ny.gov/diseases/communicable/lyme/
- API
County to CBSA Mapping for Large Metros
data.bayareametro.gov | Last Updated 2022-08-26T07:12:04.000ZData contains counties in the following list of CBSAS (per OMB Mar 2020 definition): Bay Area CBSAs: San Francisco-Oakland-Berkeley, CA San Jose-Sunnyvale-Santa Clara, CA Napa, CA Santa Rosa-Petaluma, CA Other CBSAs: Los Angeles-Long Beach-Anaheim, CA Washington-Arlington-Alexandria, DC-VA-MD-WV Denver-Aurora-Lakewood, CO Detroit-Warren-Dearborn, MI Philadelphia-Camden-Wilmington, PA-NJ-DE-MD Boston-Cambridge-Newton, MA-NH New York-Newark-Jersey City, NY-NJ-PA Phoenix-Mesa-Chandler, AZ Houston-The Woodlands-Sugar Land, TX Seattle-Tacoma-Bellevue, WA Atlanta-Sandy Springs-Alpharetta, GA Chicago-Naperville-Elgin, IL-IN-WI Austin-Round Rock-Georgetown, TX Dallas-Fort Worth-Arlington, TX Miami-Fort Lauderdale-Pompano Beach, FL
- API
Risk of Infected Blacklegged Tick Encounter: Nymphs (May to Sep): Beginning 2008
health.data.ny.gov | Last Updated 2024-05-07T14:49:16.000ZTick-borne diseases, such as Lyme disease, anaplasmosis and babesiosis, are a significant issue in New York (NY), impacting well over 10,000 individuals yearly. The New York State Department of Health (NYSDOH) has a responsibility to perform surveillance to monitor and track different kinds of tick-borne diseases. While most surveillance is done via reportable cases of human illness, tick-borne diseases can also be monitored by collecting ticks from the environment (called active surveillance) and testing them for bacteria, viruses, and parasites known to cause illness in people (collectively called pathogens). Active surveillance allows local county health departments in NY, excluding New York City (NYC), to have a better understanding of the tick populations present in the state, the species composition of the tick population, and the rate at which ticks are infected with different pathogens. The Department started testing ticks in 2002 in limited areas; testing statewide began in 2008. Further information on NYSDOH active tick surveillance can be found at the URL below and in the Data Methodology section below. https://www.health.ny.gov/diseases/communicable/lyme/